Literature DB >> 1812371

High-dose applications of gadolinium chelates in magnetic resonance imaging.

V M Runge1, J E Kirsch, G S Thomas.   

Abstract

Administration of gadolinium chelates at doses greater than 0.1 mmol/kg IV can potentially improve both lesion detection and the assessment of tissue perfusion. Preliminary results are presented in clinical patients and two animal models. In human intracranial metastatic disease, administration of 0.3 (cumulative dose) mmol/kg gadoteridol (Gd HP-DO3A) has permitted detection of additional lesions not visualized at 0.1 mmol/kg. In a rabbit model of focal liver disease, 0.5 mmol/kg IV provided superior enhancement of both normal parenchyma and lesion rim compared to doses of 0.25 and 0.1. Dynamic imaging (T1-weighted turbo-FLASH) immediately following bolus injection of 0.5 mmol/kg permitted direct visualization (on unsubtracted images) of an acute perfusion defect in the cat brain not visible on conventional T1- and T2-weighted scans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812371     DOI: 10.1002/mrm.1910220241

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  4 in total

1.  Brain MR post-gadolinium contrast in multiple sclerosis: the role of magnetization transfer and image subtraction in detecting more enhancing lesions.

Authors:  M M Gavra; C Voumvourakis; A D Gouliamos; C Sfagos; L J Vlahos
Journal:  Neuroradiology       Date:  2004-02-19       Impact factor: 2.804

2.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

3.  Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas.

Authors:  Young Kon Kim; Young Hwan Lee; Chong Soo Kim; Young Min Han; Seung Bae Hwang
Journal:  Eur Radiol       Date:  2007-04-03       Impact factor: 5.315

4.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.

Authors:  M Filippi; A Campi; V Martinelli; B Colombo; T Yousry; N Canal; G Scotti; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.